Therapeutical aspects in chronic hepatitis B
April 20, 2011
| Abstract Title: | Therapeutical aspects in chronic hepatitis B |
| Authors: | Carmen Maler, Ioana Haiduc |
| Affiliation: | Western University "Vasile Goldis" Arad, Romania |
| Abstract text: | The indication of treatment in HBe Ag positive chronic hepatitis B and in HBe Ag negative chronic hepatitis B is established after the evaluation of three criteria: DNA-HBV level, aminotransferase level and histological staging. Therapeutical strategy in chronic hepatitis B is determined by each particular case. Recommended first–line drugs are Peginterferon, Entecavir and Tenofovir. Finite theraphy with Peginterferon is effective for the patients with A and B genotype, but the results in the cases of patients with D genotype are worse. Nucleoside/nucleotide analogs have minimal adverse effects but they develop resistance over time. The duration of treatment with nucleoside/nucleotide analogs is now unclear to the HBeAg negative chronic hepatitis B. The treatment with analogs in HBeAg positive chronic hepatitis B must be maintained at least another six months (preferably twelve months) at the time of seroconversion. The aim of anitiviral therapy is to obtain a sustained immune control (loss of the HBeAg), sustained suppression of DNA-HBV, appearance of anti-HBs antibodies and extremely low levels of ccc DNA (under 0,002 copies/hepatocyte). A combination of either Peginterferon and analogs or two analogs is suggested as a future possibility. |
| Keywords: | Nucleoside/nucleotide analogs, Peginterferon |
| Presentation type: | Poster |
| Correspondence: | Carmen Maler, Arad str. Vezuviu nr.7,310218 |
| Email: | maler_sergiu@yahoo.com |
About The Author
